Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2013

Open Access 01-12-2013 | Research article

Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

Authors: Kyle Fahrbach, Rachel Huelin, Amber L Martin, Edward Kim, Homa B Dastani, Stephen Rao, Manoj Malhotra

Published in: BMC Neurology | Issue 1/2013

Login to get access

Abstract

Background

In the treatment of multiple sclerosis (MS), the most important therapeutic aim of disease-modifying treatments (DMTs) is to prevent or postpone long-term disability. Given the typically slow progression observed in the majority of relapsing-remitting MS (RRMS) patients, the primary endpoint for most randomized clinical trials (RCTs) is a reduction in relapse rate. It is widely assumed that reducing relapse rate will slow disability progression. Similarly, MRI studies suggest that reducing T2 lesions will be associated with slowing long-term disability in MS. The objective of this study was to evaluate the relationship between treatment effects on relapse rates and active T2 lesions to differences in disease progression (as measured by the Expanded Disability Status Scale [EDSS]) in trials evaluating patients with clinically isolated syndrome (CIS), RRMS, and secondary progressive MS (SPMS).

Methods

A systematic literature review was conducted in Medline, Embase, CENTRAL, and PsycINFO to identify randomized trials published in English from January 1, 1993-June 3, 2013 evaluating DMTs in adult MS patients using keywords for CIS, RRMS, and SPMS combined with keywords for relapse and recurrence. Eligible studies were required to report outcomes of relapse and T2 lesion changes or disease progression in CIS, RRMS, or SPMS patients receiving DMTs and have a follow-up duration of at least 22 months. Ultimately, 40 studies satisfied these criteria for inclusion. Regression analyses were conducted on RCTs to relate differences between the effect of treatments on relapse rates and on active T2 lesions to differences between the effects of treatments on disease progression (as measured by EDSS).

Results

Regression analysis determined there is a substantive clinically and statistically significant association between concurrent treatment effects in relapse rate and EDSS; p < 0.01. Lower treatment effects were associated with higher relative rates of disease progression. Significant associations between T2 lesion measures and EDSS measures also were found (p < 0.05), with some suggestion that the strength of the association may differ for older versus newer DMTs.

Conclusions

Treatment differences in relapse reduction and T2 lesions are positively related to differences in disease progression over the first two years of treatment.
Appendix
Available only for authorised users
Literature
1.
Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, et al: Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology. 2002, 58: 169-178. 10.1212/WNL.58.2.169.CrossRefPubMed
2.
Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H: Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010, 133: 2983-2998. 10.1093/brain/awq250.CrossRefPubMed
3.
Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N: Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008, 255: 280-287. 10.1007/s00415-008-0743-8.CrossRefPubMed
4.
Rio J, Rovira A, Tintore M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X: Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008, 14: 479-484. 10.1177/1352458507085555.CrossRefPubMed
5.
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain. 1989, 112 (Pt 1): 133-146.CrossRefPubMed
6.
Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P: Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology. 2010, 75: 302-309. 10.1212/WNL.0b013e3181ea15aa.CrossRefPubMed
7.
Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology. 2006, 7: 741-746. 10.1016/S1470-2045(06)70800-2.CrossRefPubMed
8.
Ebers GC: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial: the IFNB multiple sclerosis study group. Neurology. 1993, 43: 655-661.CrossRef
9.
Ebers GC: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet. 1998, 352: 1498-1504. 10.1016/S0140-6736(98)03334-0.CrossRef
10.
Francis G: Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology. 2001, 56: 1496-1504.CrossRef
11.
Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I: Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology. 1998, 50: 398-402. 10.1212/WNL.50.2.398.CrossRefPubMed
12.
Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sorensen P: Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004, 75: 706-710. 10.1136/jnnp.2003.010090.CrossRefPubMedPubMedCentral
13.
Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Mertin J: A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult Scler. 2005, 11: 166-168. 10.1191/1352458505ms1132oa.CrossRefPubMed
14.
Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology. 2002, 59: 1507-1517. 10.1212/01.WNL.0000032256.35561.D6.CrossRefPubMed
15.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, et al: Benefit of interferon (beta)-1a on MSFC progression in secondary progressive MS. Neurology. 2002, 59: 679-687. 10.1212/WNL.59.5.679.CrossRefPubMed
16.
Coles AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008, 359: 1786-1801.CrossRefPubMed
17.
Comi G, Filippi M, Wolinsky JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001, 49: 290-297. 10.1002/ana.64.CrossRefPubMed
18.
Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002, 359: 1453-1460. 10.1016/S0140-6736(02)08430-1.CrossRefPubMed
19.
Etemadifar M, Janghorbani M, Shaygannejad V: Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006, 113: 283-287.CrossRefPubMed
20.
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis: Austrian immunoglobulin in multiple sclerosis study group. Lancet. 1997, 349: 589-593. 10.1016/S0140-6736(96)09377-4.CrossRefPubMed
21.
Freedman MS, Francis GS, Sanders EA, Rice GP, O’Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, et al: Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler. 2005, 11: 41-45. 10.1191/1352458505ms1126oa.CrossRefPubMed
22.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ: A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010, 362: 416-426. 10.1056/NEJMoa0902533.CrossRefPubMed
23.
Gonsette RE, Sindic C, D’Hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D: Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of inosine and interferon (beta) in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler. 2010, 16: 455-462. 10.1177/1352458509360547.CrossRefPubMed
24.
Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T, Albrecht H, Basedow-Rajwich B, et al: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002, 360: 2018-2025. 10.1016/S0140-6736(02)12023-X.CrossRefPubMed
25.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, et al: Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler. 2009, 15: 965-976. 10.1177/1352458509105229.CrossRefPubMed
26.
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996, 39: 285-294. 10.1002/ana.410390304.CrossRefPubMed
27.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: the copolymer 1 multiple sclerosis study group. Neurology. 1995, 45: 1268-1276. 10.1212/WNL.45.7.1268.CrossRefPubMed
28.
Kappos L: Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998, 352: 1491-1497. 10.1016/S0140-6736(98)10039-9.CrossRef
29.
Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, et al: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006, 67: 1242-1249. 10.1212/01.wnl.0000237641.33768.8d.CrossRefPubMed
30.
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362: 387-401. 10.1056/NEJMoa0909494.CrossRefPubMed
31.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, et al: Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010, 16: 450-454. 10.1177/1352458509358909.CrossRefPubMed
32.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008, 7: 903-914. 10.1016/S1474-4422(08)70200-X.CrossRefPubMed
33.
Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, et al: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997, 244: 153-159. 10.1007/s004150050066.CrossRefPubMed
34.
O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, et al: 250 (mu)g or 500 (mu)g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009, 8: 889-897. 10.1016/S1474-4422(09)70226-1.CrossRefPubMed
35.
Panitch H: Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004, 63: 1788-1795.CrossRefPubMed
36.
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006, 354: 899-910. 10.1056/NEJMoa044397.CrossRefPubMed
37.
Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholome E, Constantinescu CS, Beer K, Garde E, Sperling B: Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010, 9: 672-680. 10.1016/S1474-4422(10)70132-0.CrossRefPubMed
38.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006, 354: 911-923. 10.1056/NEJMoa044396.CrossRefPubMed
39.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Sogaard LV, Olsen IC, Sandberg-Wollheim M: NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009, 8: 519-529. 10.1016/S1474-4422(09)70085-7.CrossRefPubMed
40.
Van De Wyngaert FA, Beguin C, D’Hooghe MB, Dooms G, Lissoir F, Carton H, Sindic CJM: A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurologica Belgica. 2001, 101: 210-216.PubMed
41.
Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M: Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011, 82: 1344-1350. 10.1136/jnnp.2010.229724.CrossRefPubMed
42.
Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, et al: A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011, 77: 1551-1560. 10.1212/WNL.0b013e318233b240.CrossRefPubMed
43.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, et al: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012, 380: 1819-1828. 10.1016/S0140-6736(12)61769-3.CrossRefPubMed
44.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, et al: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012, 380: 1829-1839. 10.1016/S0140-6736(12)61768-1.CrossRefPubMed
45.
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, Group AS: Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012, 366: 1000-1009. 10.1056/NEJMoa1104318.CrossRefPubMed
46.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012, 367: 1087-1097. 10.1056/NEJMoa1206328.CrossRefPubMed
47.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, et al: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012, 367: 1098-1107. 10.1056/NEJMoa1114287.CrossRefPubMed
Metadata
Title
Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis
Authors
Kyle Fahrbach
Rachel Huelin
Amber L Martin
Edward Kim
Homa B Dastani
Stephen Rao
Manoj Malhotra
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2013
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-13-180

Other articles of this Issue 1/2013

BMC Neurology 1/2013 Go to the issue

Research article

Increased leptin and A-FABP levels in relapsing and progressive forms of MS

Research article

OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review

Research article

Risk factors, quality of care and prognosis in South Asian, East Asian and White patients with stroke

Research article

Temporal trends in stroke admissions in Denmark 1997–2009

Research article

Jugular venous reflux and plasma endothelin-1 are associated with cough syncope: a case control pilot study

Research article

Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study